Cargando…

A novel approach to characterize phenotypic variation in GSD IV: Reconceptualizing the clinical continuum

Purpose: Glycogen storage disease type IV (GSD IV) has historically been divided into discrete hepatic (classic hepatic, non-progressive hepatic) and neuromuscular (perinatal-congenital neuromuscular, juvenile neuromuscular) subtypes. However, the extent to which this subtype-based classification sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiely, Bridget T., Koch, Rebecca L., Flores, Leticia, Burner, Danielle, Kaplan, Samantha, Kishnani, Priya S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513518/
https://www.ncbi.nlm.nih.gov/pubmed/36176296
http://dx.doi.org/10.3389/fgene.2022.992406
_version_ 1784798081762459648
author Kiely, Bridget T.
Koch, Rebecca L.
Flores, Leticia
Burner, Danielle
Kaplan, Samantha
Kishnani, Priya S.
author_facet Kiely, Bridget T.
Koch, Rebecca L.
Flores, Leticia
Burner, Danielle
Kaplan, Samantha
Kishnani, Priya S.
author_sort Kiely, Bridget T.
collection PubMed
description Purpose: Glycogen storage disease type IV (GSD IV) has historically been divided into discrete hepatic (classic hepatic, non-progressive hepatic) and neuromuscular (perinatal-congenital neuromuscular, juvenile neuromuscular) subtypes. However, the extent to which this subtype-based classification system accurately captures the landscape of phenotypic variation among GSD IV patients has not been systematically assessed. Methods: This study synthesized clinical data from all eligible cases of GSD IV in the published literature to evaluate whether this disorder is better conceptualized as discrete subtypes or a clinical continuum. A novel phenotypic scoring approach was applied to characterize the extent of hepatic, neuromuscular, and cardiac involvement in each eligible patient. Results: 146 patients met all inclusion criteria. The majority (61%) of those with sufficient data to be scored exhibited phenotypes that were not fully consistent with any of the established subtypes. These included patients who exhibited combined hepatic-neuromuscular involvement; patients whose phenotypes were intermediate between the established hepatic or neuromuscular subtypes; and patients who presented with predominantly cardiac disease. Conclusion: The application of this novel phenotypic scoring approach showed that–in contrast to the traditional subtype-based view–GSD IV may be better conceptualized as a multidimensional clinical continuum, whereby hepatic, neuromuscular, and cardiac involvement occur to varying degrees in different patients.
format Online
Article
Text
id pubmed-9513518
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95135182022-09-28 A novel approach to characterize phenotypic variation in GSD IV: Reconceptualizing the clinical continuum Kiely, Bridget T. Koch, Rebecca L. Flores, Leticia Burner, Danielle Kaplan, Samantha Kishnani, Priya S. Front Genet Genetics Purpose: Glycogen storage disease type IV (GSD IV) has historically been divided into discrete hepatic (classic hepatic, non-progressive hepatic) and neuromuscular (perinatal-congenital neuromuscular, juvenile neuromuscular) subtypes. However, the extent to which this subtype-based classification system accurately captures the landscape of phenotypic variation among GSD IV patients has not been systematically assessed. Methods: This study synthesized clinical data from all eligible cases of GSD IV in the published literature to evaluate whether this disorder is better conceptualized as discrete subtypes or a clinical continuum. A novel phenotypic scoring approach was applied to characterize the extent of hepatic, neuromuscular, and cardiac involvement in each eligible patient. Results: 146 patients met all inclusion criteria. The majority (61%) of those with sufficient data to be scored exhibited phenotypes that were not fully consistent with any of the established subtypes. These included patients who exhibited combined hepatic-neuromuscular involvement; patients whose phenotypes were intermediate between the established hepatic or neuromuscular subtypes; and patients who presented with predominantly cardiac disease. Conclusion: The application of this novel phenotypic scoring approach showed that–in contrast to the traditional subtype-based view–GSD IV may be better conceptualized as a multidimensional clinical continuum, whereby hepatic, neuromuscular, and cardiac involvement occur to varying degrees in different patients. Frontiers Media S.A. 2022-09-13 /pmc/articles/PMC9513518/ /pubmed/36176296 http://dx.doi.org/10.3389/fgene.2022.992406 Text en Copyright © 2022 Kiely, Koch, Flores, Burner, Kaplan and Kishnani. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Kiely, Bridget T.
Koch, Rebecca L.
Flores, Leticia
Burner, Danielle
Kaplan, Samantha
Kishnani, Priya S.
A novel approach to characterize phenotypic variation in GSD IV: Reconceptualizing the clinical continuum
title A novel approach to characterize phenotypic variation in GSD IV: Reconceptualizing the clinical continuum
title_full A novel approach to characterize phenotypic variation in GSD IV: Reconceptualizing the clinical continuum
title_fullStr A novel approach to characterize phenotypic variation in GSD IV: Reconceptualizing the clinical continuum
title_full_unstemmed A novel approach to characterize phenotypic variation in GSD IV: Reconceptualizing the clinical continuum
title_short A novel approach to characterize phenotypic variation in GSD IV: Reconceptualizing the clinical continuum
title_sort novel approach to characterize phenotypic variation in gsd iv: reconceptualizing the clinical continuum
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513518/
https://www.ncbi.nlm.nih.gov/pubmed/36176296
http://dx.doi.org/10.3389/fgene.2022.992406
work_keys_str_mv AT kielybridgett anovelapproachtocharacterizephenotypicvariationingsdivreconceptualizingtheclinicalcontinuum
AT kochrebeccal anovelapproachtocharacterizephenotypicvariationingsdivreconceptualizingtheclinicalcontinuum
AT floresleticia anovelapproachtocharacterizephenotypicvariationingsdivreconceptualizingtheclinicalcontinuum
AT burnerdanielle anovelapproachtocharacterizephenotypicvariationingsdivreconceptualizingtheclinicalcontinuum
AT kaplansamantha anovelapproachtocharacterizephenotypicvariationingsdivreconceptualizingtheclinicalcontinuum
AT kishnanipriyas anovelapproachtocharacterizephenotypicvariationingsdivreconceptualizingtheclinicalcontinuum
AT kielybridgett novelapproachtocharacterizephenotypicvariationingsdivreconceptualizingtheclinicalcontinuum
AT kochrebeccal novelapproachtocharacterizephenotypicvariationingsdivreconceptualizingtheclinicalcontinuum
AT floresleticia novelapproachtocharacterizephenotypicvariationingsdivreconceptualizingtheclinicalcontinuum
AT burnerdanielle novelapproachtocharacterizephenotypicvariationingsdivreconceptualizingtheclinicalcontinuum
AT kaplansamantha novelapproachtocharacterizephenotypicvariationingsdivreconceptualizingtheclinicalcontinuum
AT kishnanipriyas novelapproachtocharacterizephenotypicvariationingsdivreconceptualizingtheclinicalcontinuum